Valuation: AstraZeneca PLC

Market Cap 255B 218B 204B 187B 351B 24,411B 358B 2,418B 943B 12,234B 958B 937B 40,503B P/E 2026 *
21x
P/E 2027 * 18.3x
Enterprise Value 274B 235B 219B 201B 378B 26,261B 385B 2,601B 1,014B 13,161B 1,031B 1,008B 43,571B EV / Sales 2026 *
4.34x
EV / Sales 2027 * 3.99x
Free-Float
96.63%
Yield 2026 *
2.03%
Yield 2027 * 2.15%
1 day-12.35%
Current year+1.81%
Current year 152.4
Extreme 152.4
166.3
1 year 124.15
Extreme 124.15
166.3
3 years 111
Extreme 111
166.3
5 years 94.29
Extreme 94.29
166.3
10 years 47.72
Extreme 47.715
166.3
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Compliance Officer - 31/12/2022
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-12.34%0.00% - - 254B
-2.75%+3.45%+77.29%+127.38% 1,141B
-2.02%+2.63%+50.40%+60.72% 659B
-1.94%+4.49%+25.31%+74.53% 470B
+1.20%+2.62%+41.69%+46.21% 366B
-0.61%+2.10%+23.43%+40.38% 302B
+0.32%+3.25%+0.94%+13.25% 254B
-2.15%+3.64%+46.08%+66.11% 239B
-1.10%-0.70%-14.31%-53.04% 207B
-2.19%+4.92%+22.08%+90.86% 183B
Average -2.40%+4.10%+30.32%+51.82% 424.55B
Weighted average by Cap. -2.30%+4.31%+43.96%+71.80%

Financials

2026 *2027 *
Net sales 63.25B 54.15B 50.53B 46.36B 87.12B 6,052B 88.83B 599B 234B 3,033B 237B 232B 10,041B 66.84B 57.23B 53.39B 48.99B 92.06B 6,395B 93.87B 633B 247B 3,205B 251B 246B 10,611B
Net income 12.07B 10.33B 9.64B 8.85B 16.63B 1,155B 16.95B 114B 44.59B 579B 45.32B 44.33B 1,916B 13.72B 11.74B 10.96B 10.05B 18.89B 1,312B 19.26B 130B 50.67B 658B 51.5B 50.38B 2,177B
Net Debt 19.33B 16.55B 15.44B 14.17B 26.62B 1,849B 27.14B 183B 71.4B 927B 72.57B 70.99B 3,068B 11.65B 9.98B 9.31B 8.54B 16.05B 1,115B 16.37B 110B 43.05B 559B 43.75B 42.8B 1,850B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
163.97USD
Average target price
212.30USD
Spread / Average Target
+29.47%

Quarterly revenue - Rate of surprise